Alerts will be sent to your verified email
Verify Email
NOVARTIND
|
Novartis
|
Indoco Remedies
|
Panacea Biotec
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
8.0 % | 8.94 % | 17.16 % |
|
5yr Avg Net Profit Margin
|
17.12 % | 5.41 % | 19.26 % |
|
Price to Book
|
2.94 | 2.41 | 3.06 |
|
P/E
|
22.42 | 0.0 | 222.38 |
|
5yr Avg Cash Conversion Cycle
|
-23.33 Days | 35.3 Days | -102.87 Days |
|
5yr Average Interest Coverage Ratio
|
65.43 | 7.53 | 2.9 |
|
5yr Avg ROCE
|
5.91 % | 13.6 % | -1.68 % |
|
5yr Avg Operating Profit Margin
|
15.15 % | 14.97 % | -1.99 % |
|
5 yr average Debt to Equity
|
0.0 | 0.49 | 0.05 |
|
5yr CAGR Net Profit
|
37.01 % | n/a | -64.03 % |
|
5yr Average Return on Assets
|
3.13 % | 5.31 % | 6.95 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
70.68 % | 58.9 % | 72.48 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.21 % | -1.11 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 1.16 % | 0.0 |
|
Novartis
|
Indoco Remedies
|
Panacea Biotec
|
|---|